Review Article
Alloreactivity of Allogeneic Mesenchymal Stem/Stromal Cells and Other Cellular Therapies: A Concise Review
Table 1
Current MSC-approved products for human clinical use.
| | Source of human tissue | Clinical condition | Trade name | Company | Approving country and year of approval |
| | Adipose | Complex perianal fistulas in CD | ALOFISEL | TiGenix NV/Takeda | Europe (2018) | | Bone Marrow | Spinal cord injury | STEMIRAC | Nipro Corp. | Japan (2018) | | Bone Marrow | Critical limb ischemia | STEMPEUCEL | Stempeutics Research PVT | India (2016) | | Bone Marrow | GvHD | TEMCELL HS INJ | JCR Pharmaceuticals | Japan (2015) | | Bone Marrow | Amytrophic lateral sclerosis | NEURONATA-R | Corestem Inc. | South Korea (2014) | | Bone Marrow | GvHD | PROCHYMAL | Osiris Therapeutics Inc./ | Canada (2012) | | | (REMESTEMCEL-L) | Mesoblast Ltd. | New Zealand (2012) | | Adipose | Crohn’s fistula | CUPISTEM | Anterogen Co. Ltd | South Korea (2012) | | Umbilical Cord | Knee articular cartilage defects | CARTISTEM | Medipost Co. Ltd. | South Korea (2012) | | Bone Marrow | Acute MI | CELLGRAM-AMI | Pharmicell Co. Ltd. | South Korea (2011) | | Adipose | Subcutaneous tissue defects | QUEENCELL | Anterogen Co. Ltd. | South Korea (2010) |
|
|
